SAR 113945
/ Sanofi
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 26, 2025
Advances and Challenges in the Pursuit of Disease-Modifying Osteoarthritis Drugs: A Review of 2010-2024 Clinical Trials.
(PubMed, Biomedicines)
- " Eleven DMOAD candidates are reviewed and critically analyzed for their potential benefit in OA treatment-Lorecivivint (SM04690), TissueGene-C, Cindunistat (SD-6010), Sprifermin, UBX0101, TPX-100, GLPG1972/S201086, Lutikizumab (ABT-981), SAR113945, MIV-711, and LNA043-and relevant challenges to their development are discussed. Six DMOADs have demonstrated statistically significant evidence of a structural or symptomatic benefit without major safety concerns in phase II and III randomized controlled trials post-2010."
Journal • Review • Developmental Disorders • Immunology • Osteoarthritis • Pain • Rheumatology
1 to 1
Of
1
Go to page
1